AU2014262474B2 - In vitro production of red blood cells with sortaggable proteins - Google Patents

In vitro production of red blood cells with sortaggable proteins Download PDF

Info

Publication number
AU2014262474B2
AU2014262474B2 AU2014262474A AU2014262474A AU2014262474B2 AU 2014262474 B2 AU2014262474 B2 AU 2014262474B2 AU 2014262474 A AU2014262474 A AU 2014262474A AU 2014262474 A AU2014262474 A AU 2014262474A AU 2014262474 B2 AU2014262474 B2 AU 2014262474B2
Authority
AU
Australia
Prior art keywords
red blood
sortase
blood cell
protein
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014262474A
Other languages
English (en)
Other versions
AU2014262474A1 (en
Inventor
Lenka KUNDRAT
Hsiang-Ying LEE
Harvey Lodish
Novalia PISHESHA
Hidde L. Ploegh
Jiahai SHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Publication of AU2014262474A1 publication Critical patent/AU2014262474A1/en
Application granted granted Critical
Publication of AU2014262474B2 publication Critical patent/AU2014262474B2/en
Priority to AU2019283766A priority Critical patent/AU2019283766B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2014262474A 2013-05-10 2014-05-09 In vitro production of red blood cells with sortaggable proteins Ceased AU2014262474B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019283766A AU2019283766B2 (en) 2013-05-10 2019-12-16 In vitro production of red blood cells with sortaggable proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822071P 2013-05-10 2013-05-10
US61/822,071 2013-05-10
PCT/US2014/037554 WO2014183071A2 (en) 2013-05-10 2014-05-09 In vitro production of red blood cells with sortaggable proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019283766A Division AU2019283766B2 (en) 2013-05-10 2019-12-16 In vitro production of red blood cells with sortaggable proteins

Publications (2)

Publication Number Publication Date
AU2014262474A1 AU2014262474A1 (en) 2015-12-17
AU2014262474B2 true AU2014262474B2 (en) 2019-10-31

Family

ID=51867887

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014262474A Ceased AU2014262474B2 (en) 2013-05-10 2014-05-09 In vitro production of red blood cells with sortaggable proteins
AU2019283766A Ceased AU2019283766B2 (en) 2013-05-10 2019-12-16 In vitro production of red blood cells with sortaggable proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019283766A Ceased AU2019283766B2 (en) 2013-05-10 2019-12-16 In vitro production of red blood cells with sortaggable proteins

Country Status (7)

Country Link
US (3) US10471099B2 (OSRAM)
EP (4) EP3546484B1 (OSRAM)
JP (3) JP6599848B2 (OSRAM)
AU (2) AU2014262474B2 (OSRAM)
ES (1) ES2901383T3 (OSRAM)
HK (1) HK1222662A1 (OSRAM)
WO (1) WO2014183071A2 (OSRAM)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103764665A (zh) 2011-06-28 2014-04-30 怀特黑德生物医学研究所 使用分选酶安装用于蛋白质连接的点击化学柄
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
WO2014183071A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research In vitro production of red blood cells with sortaggable proteins
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
CA2930015A1 (en) 2013-11-07 2015-05-14 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
RU2736495C2 (ru) 2014-04-01 2020-11-17 Рубиус Терапьютикс, Инк. Способ и композиции для иммуномодуляции
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10053683B2 (en) 2014-10-03 2018-08-21 Whitehead Institute For Biomedical Research Intercellular labeling of ligand-receptor interactions
RU2711364C2 (ru) 2014-12-17 2020-01-16 Ф. Хоффманн-Ля Рош Аг Ферментативная однореакторная реакция двойного конъюгирования полипептидов за одну стадию с использованием сортазы
CN107109463B (zh) 2014-12-17 2020-12-29 豪夫迈·罗氏有限公司 键形成酶的活性测定
US20180135012A1 (en) * 2015-05-13 2018-05-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
WO2017050872A1 (en) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Transamidation employing sortase a in deep eutectic solvents
JP6895953B2 (ja) 2015-09-25 2021-06-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ソルターゼａを利用してチオエステルを作製するための方法
WO2017059397A1 (en) 2015-10-01 2017-04-06 Whitehead Institute For Biomedical Research Labeling of antibodies
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
RS62939B1 (sr) 2016-01-11 2022-03-31 Rubius Therapeutics Inc Kompozicije i metode u vezi sa multimodalnim terapijskim ćelijskim sistemima u indikacijama kancera
WO2017124102A1 (en) 2016-01-14 2017-07-20 North Carolina State University Glucose responsive insulin delivery compositions and methods
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
JP7588390B2 (ja) 2016-10-14 2024-11-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基エディターのａａｖ送達
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US20180153989A1 (en) 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
BR112019016951A2 (pt) 2017-02-17 2020-05-26 Rubius Therapeutics, Inc. Células eritroides funcionalizadas
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
BR112019019655A2 (pt) 2017-03-23 2020-04-22 Harvard College editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2019017940A1 (en) * 2017-07-19 2019-01-24 Rubius Therapeutics, Inc. COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIMODAL THERAPEUTIC CELLULAR SYSTEMS FOR THE TREATMENT OF INFECTIOUS DISEASE
EP3654992A1 (en) 2017-07-19 2020-05-27 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic disease
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
EP3664830A4 (en) * 2017-08-07 2020-07-01 The Regents of the University of California RISK-FREE CELL THERAPEUTIC GENERATION PLATFORM
US10960071B2 (en) * 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
WO2019040516A1 (en) 2017-08-22 2019-02-28 Rubius Therapeutics, Inc. METHODS AND COMPOSITIONS OF LIPID NANOPARTICLES FOR THE PRODUCTION OF MODIFIED ERYTHROID CELLS
US20200206269A1 (en) * 2017-08-23 2020-07-02 Whitehead Institute For Biomedical Research Production of enucleated red blood cells and uses thereof
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US20190160102A1 (en) 2017-11-03 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3727434A1 (en) * 2017-12-23 2020-10-28 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use
US20190201548A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for engineering erythroid cells
US20190330591A1 (en) 2018-01-10 2019-10-31 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
CN112105723A (zh) 2018-03-08 2020-12-18 鲁比厄斯治疗法股份有限公司 用于治疗癌症和传染病的治疗性细胞系统和方法
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
CN112996543A (zh) * 2018-09-21 2021-06-18 香港城市大学 表面修饰的细胞外囊泡
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
CA3121258A1 (en) 2018-12-03 2020-06-11 Rubius Therapeutics, Inc. Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
KR20210135008A (ko) 2019-02-20 2021-11-12 루비우스 테라퓨틱스, 아이엔씨. 적재가능한 항원 제시 폴리펩타이드를 포함하는 조작된 적혈구계 세포 및 이의 사용 방법
EP3942042A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
JP2022530130A (ja) 2019-04-26 2022-06-27 ルビウス セラピューティクス， インコーポレイテッド 除核赤血球細胞を含む緩衝組成物
WO2020243006A1 (en) 2019-05-24 2020-12-03 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021092047A1 (en) 2019-11-04 2021-05-14 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using taurine or hypotaurine
CA3159917A1 (en) 2019-11-04 2021-05-14 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using myo-inositol
US20230050813A1 (en) 2020-01-13 2023-02-16 Carmine Therapeutics Pte. Ltd. Nucleic acid loaded red blood cell extracellular vesicles
CN115397395A (zh) * 2020-02-07 2022-11-25 加利福尼亚大学董事会 生物工程去核细胞的方法和用途
CN115151636A (zh) 2020-02-10 2022-10-04 鲁比厄斯治疗法股份有限公司 包含hla-g多肽的经工程改造的红系细胞及其使用方法
WO2021185360A1 (en) * 2020-03-20 2021-09-23 Westlake Therapeutics (Hangzhou) Co., Limited Novel truncated sortase variants
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
AU2021270347A1 (en) * 2020-05-11 2022-12-15 Erytech Pharma Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof
WO2022089605A1 (en) * 2020-10-30 2022-05-05 Westlake Therapeutics (Hangzhou) Co. Limited Modified red blood cells and uses thereof for delivering agents
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022150569A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. METHODS OF INCREASING NKp30-POSITIVE LYMPHOCYTES IN A SUBJECT AND USES THEREOF
WO2022150578A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. Methods of treating a tumor in a human subject
WO2022164392A1 (en) * 2021-01-29 2022-08-04 National University Of Singapore Surface modified red blood cells and methods of generating the same
CN116888258A (zh) * 2021-02-04 2023-10-13 西湖生物医药科技(杭州)有限公司 修饰的红细胞及其治疗高尿酸血症和痛风的用途
WO2022197548A1 (en) 2021-03-14 2022-09-22 Rubius Therapeutics, Inc. Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof
WO2022211740A1 (en) 2021-03-31 2022-10-06 Carmine Therapeutics Pte. Ltd. Extracellular vesicles loaded with at least two different nucleic acids
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法
WO2023284742A1 (en) * 2021-07-13 2023-01-19 Westlake Therapeutics (Hangzhou) Co. Limited Cells modified by conjugated n-terminal glycine and uses thereof
WO2024088213A1 (en) * 2022-10-24 2024-05-02 Westlake Therapeutics (Shanghai) Co., Limited Combination to induce specific immune tolerance
WO2024215885A2 (en) * 2023-04-12 2024-10-17 Cytonus Therapeutics, Inc. Manufacturing of therapeutic cells
WO2025006882A1 (en) * 2023-06-30 2025-01-02 The Children's Hospital Of Philadelphia Click chemistry assisted cell surface engineering for restoring lentivirus entry

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211656B2 (en) * 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5670132A (en) 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
JP2000501614A (ja) 1995-12-15 2000-02-15 システミックス，インコーポレイテッド 高形質導入効率を有するレトロウイルスベクター上清を得るための方法
AU784043B2 (en) 1999-04-15 2006-01-19 Regents Of The University Of California, The Identification of sortase gene
US20020122768A1 (en) 2000-07-06 2002-09-05 Shuang Liu Stable radiopharmaceutical compositions and methods for preparation thereof
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US6960473B2 (en) * 2003-02-27 2005-11-01 Istituto Superiore Di Sanita In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients
WO2005051976A2 (en) 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
US20090098611A1 (en) 2004-02-27 2009-04-16 Wood David W Self-cleaving affinity tags and methods of use
CA2566561C (en) * 2004-06-04 2013-01-08 Universite Pierre Et Marie Curie - Paris Vi A method for producing red blood cells
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
US20120034157A1 (en) 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
JP2010115136A (ja) 2008-11-12 2010-05-27 Teruyuki Nagamune Ｎ末端標識膜蛋白質の作製方法、及びｎ末端標識膜蛋白質を表層に有する細胞
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
BR112012020958A2 (pt) * 2010-02-22 2015-09-15 Univ Paris Curie "meio de cultura para a criação e/ou diferenciação de células da linhagem hemapo
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
US20130122043A1 (en) 2010-04-20 2013-05-16 Whitehead Institute For Biomedical Research Modified polypeptides and proteins and uses thereof
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
CN103764665A (zh) 2011-06-28 2014-04-30 怀特黑德生物医学研究所 使用分选酶安装用于蛋白质连接的点击化学柄
CN102559600A (zh) 2011-12-29 2012-07-11 上海交通大学医学院 一种人工抗原递呈细胞及其在nk细胞扩增中的应用
CN104159911A (zh) 2012-03-07 2014-11-19 奥瑞基尼探索技术有限公司 作为免疫调节剂的模拟肽化合物
US9751945B2 (en) 2012-04-13 2017-09-05 Whitehead Institute For Biomedical Research Sortase-modified VHH domains and uses thereof
US20140030697A1 (en) 2012-06-14 2014-01-30 Massachusetts Institute Of Technology Sortase-mediated modification of viral surface proteins
US9267127B2 (en) 2012-06-21 2016-02-23 President And Fellows Of Harvard College Evolution of bond-forming enzymes
US9511350B2 (en) 2013-05-10 2016-12-06 Clean Diesel Technologies, Inc. (Cdti) ZPGM Diesel Oxidation Catalysts and methods of making and using same
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
WO2014183071A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research In vitro production of red blood cells with sortaggable proteins
CN111876387A (zh) 2013-05-15 2020-11-03 罗切斯特大学 人广泛自我更新型成红细胞(esre)
WO2015051188A1 (en) 2013-10-02 2015-04-09 Washington University Heterocyclic molecules for biomedical imaging and therapeutic applications
WO2015057863A1 (en) 2013-10-15 2015-04-23 Regents Of The University Of Minnesota Triorthogonal reagents for dual protein conjugation
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
US10053683B2 (en) 2014-10-03 2018-08-21 Whitehead Institute For Biomedical Research Intercellular labeling of ligand-receptor interactions
US20180135012A1 (en) 2015-05-13 2018-05-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
WO2017059397A1 (en) 2015-10-01 2017-04-06 Whitehead Institute For Biomedical Research Labeling of antibodies
US20200206269A1 (en) 2017-08-23 2020-07-02 Whitehead Institute For Biomedical Research Production of enucleated red blood cells and uses thereof
WO2020243006A1 (en) * 2019-05-24 2020-12-03 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211656B2 (en) * 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same

Also Published As

Publication number Publication date
HK1222662A1 (zh) 2017-07-07
JP6960177B2 (ja) 2021-11-05
EP3546484A1 (en) 2019-10-02
JP6599848B2 (ja) 2019-10-30
AU2014262474A1 (en) 2015-12-17
US10471099B2 (en) 2019-11-12
WO2014183071A3 (en) 2015-01-29
US11992505B2 (en) 2024-05-28
JP2022001063A (ja) 2022-01-06
JP2016519933A (ja) 2016-07-11
AU2019283766B2 (en) 2022-01-27
EP3546485A1 (en) 2019-10-02
US11266695B2 (en) 2022-03-08
WO2014183071A2 (en) 2014-11-13
US20200069736A1 (en) 2020-03-05
US20180280440A1 (en) 2018-10-04
AU2019283766A1 (en) 2020-01-16
EP3693398A1 (en) 2020-08-12
US20160082046A1 (en) 2016-03-24
EP3546484B1 (en) 2021-09-08
EP2994491A4 (en) 2016-12-07
ES2901383T3 (es) 2022-03-22
EP2994491A2 (en) 2016-03-16
JP2020018317A (ja) 2020-02-06

Similar Documents

Publication Publication Date Title
US11992505B2 (en) In vitro production of red blood cells with proteins comprising sortase recognition motifs
EP3692063A1 (en) Hpv-specific binding molecules
WO2018067546A1 (en) Delivery of therapeutic rnas via arrdc1-mediated microvesicles
US20200206269A1 (en) Production of enucleated red blood cells and uses thereof
CN113840911A (zh) 用于在血液中或在富集pbmc中基因修饰淋巴细胞的方法和组合物
US20240076315A1 (en) Khl polypeptide, and use thereof in preparation of tabp-eic cell
US20190010211A1 (en) System for presenting peptides on the cell surface
WO2023170681A1 (en) Lentiviral vectors for in vivo targeting of immune cells
US20250207168A1 (en) Production cells
HK40034057A (en) In vitro production of red blood cells with sortaggable proteins
HK40014485A (en) In vitro production of red blood cells with sortaggable proteins
HK40014900A (en) In vitro production of red blood cells with sortaggable proteins
HK40014900B (en) In vitro production of red blood cells with sortaggable proteins
CN115485293A (zh) 用于her2的嵌合抗原受体和其使用方法
WO2023220457A1 (en) Receptor engagement-mediated enhancement of biologics delivery
CN119421890A (zh) 改进的生产细胞
AU2020226714A1 (en) Cell penetrating transposase
Winter et al. A novel pseudotype derived of the canine distemper virus for adapter-mediated lentiviral transduction in vivo
WO2025128096A1 (en) High production of recombinant protein by making cell hybrids and enriching for a preferred mitochondrial phenotype

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired